Picrorhiza kurroa (Kutki): A Comprehensive Reference
1. Identity and Botanical Description
Scientific Name and Taxonomy
Picrorhiza kurroa Royle ex Benth. is the accepted binomial name for this species. It belongs to the family Scrophulariaceae, though some modern classification systems place it within Plantaginaceae. The genus name is derived from Greek: the word Picros means bitter and Rhiza means root, reflecting the plant's most prominent sensory characteristic. The species epithet kurroa is derived from the Punjabi word karu, likewise denoting bitterness.
The plant has numerous synonyms and vernacular names across cultures. Synonyms include Picrorhiza scrophulariiflora, Picrorhiza kurroa Royle ex Benth., Kutki, Katuka, and Katuki. In Canada's Natural Health Products database it is catalogued as Picrorhiza kurrooa. The most widely used common names in English-speaking contexts are "picrorhiza" and "kutki" (or "kutaki"). In Nepali it is known as kutki (कुटकी).
Morphology and Natural Habitat
Kutki is a small, hairy, creeping, and herbaceous alpine species. It grows in rock crevices and moist, sandy soils with long creeping rootstocks that are bitter in taste. It is found in the Himalayan region from Ladakh, Kashmir to Sikkim at an elevation of 2,700–4,500 m and in Nepal, found abundantly between 3,500 and 4,800 m. Picrorhiza kurroa plantation varies from subalpine to alpine ranges of 3,000–5,300 m (msl) observed extensively across North Western to North Eastern Himalaya. In India, it grows mainly on open, rocky, grassy slopes and turf of polar surfaces in the north-western parts, along with minor occurrence in eastern and central parts.
It is found in the Himalayan regions of China, Pakistan, India, Bhutan, and Nepal. Picrorhiza kurroa and the closely related Picrorhiza scrophulariiflora Pennell are extensively used in traditional medicinal systems of China, Tibet, Nepal, India, and Sri Lanka for the treatment of various immune-related diseases.
The Medicinal Part
Picroliv is normally obtained from 3–4-year-old roots and rhizomes of the plant. Significant qualitative differences with respect to the secondary metabolites were noticed between the leaf and rhizome tissues. Leaves contained more cucurbitacins and flavonoids, while iridoids were present more in rhizomes. The rhizomes and roots are therefore the primary pharmaceutical parts. The part of P. kurroa concerned with medication is 1–3 g of the powdered crude drug.
Conservation Status
Picrorhiza kurroa has most recently been assessed for the IUCN Red List of Threatened Species in 2021 and is listed as Endangered under criteria A2cd. It is one of the most sought-after medicinal plants at the world level and is figured among the 37 identified top priority species for conservation and cultivation in the Western Himalayas, owing to its narrow distribution range, small population size, and high value. To control the illegal trade of the species, Picrorhiza kurroa was listed in Appendix II of the Convention on International Trade in Endangered Species (CITES). Around 300–400 plants are uprooted to get 1 kg of roots. Kutki is listed in CITES Appendix II and the Indian Red List of endangered species, which restricts the trade of noncultivated and nontraceable Kutki obtained from the wild.
2. Traditional and Historical Use
Ayurvedic Tradition
Picrorhiza kurroa Royle ex Benth (Kutki) is an important medicinal plant, traditionally recommended and used in Ayurveda for millennia, with certain cautions. The rhizome has a long history of use in Indian Ayurvedic medicine for the treatment of digestive problems. The Canadian government's Natural Health Products Ingredients Database formally recognizes the following traditional Ayurvedic uses: traditionally used in Ayurveda as a bitter tonic to help stimulate appetite and aid digestion (stomachic); traditionally used in Ayurveda as a hepatoprotectant/liver protectant; and traditionally used in Ayurveda as a laxative for the relief of occasional constipation.
Traditional and folk uses of P. kurroa include chronic constipation, skin-related problems, burning sensation, chronic reoccurring fever, jaundice, heart problems, breathing, digestion, allergy, tuberculosis, blood-related problems, prediabetes and obesity, laxative, cholagogue, and liver stimulatory applications. Classical Ayurvedic texts such as the Charaka Samhita and Sushruta Samhita document its use. The Sushruta Samhita mentions this herb in Mustadi Gana and Pipplayadi Gana; Katuki is also explained in various other ancient books like Bhavaprakash Nighantu, Nighantu Adarsha, Ashtang Samgraha, and Rajnighantu.
In Ayurvedic theory, the plant is characterized by its Tikta Rasa (bitter taste) and its capacity to pacify Kapha and Pitta doshas, effects summarized in some accounts as Kapha-Pitta Shamaka.
Tibetan and Trans-Himalayan Medicine
Tibetan medical experts and non-specialists use this plant's rhizomes to cure colds, coughs, skin diseases, liver diseases, fever, indigestion, jaundice, scorpion stings, hepatitis, and metabolic problems.
Unani and Related Systems
Picrorhiza kurroa is a traditional medicinal herb from the Himalayas, widely used in Ayurveda and Unani medicine for liver disorders. Its use also extends into traditional practices across Nepal, Sri Lanka, and China, where in the Ayurvedic medicine system, Picrorhiza is generally used for treatment of disorders of the liver, upper portion of the respiratory tract, to reduce fever, chronic diarrhea, dyspepsia, and scorpion sting.
Historical Preparations
Traditional preparations employed primarily the dried rhizome and root. The crude drug was used as a bitter powder, decoction, or as a constituent of compound polyherbal formulations. One notable compound preparation is Arogyavardhini (Arogyawardhini), a classical Ayurvedic formulation containing P. kurroa as a major ingredient that was historically employed for liver complaints. An earlier commonly used Ayurvedic formulation, Arogyavardhini, containing 50% P. kurroa, was also found effective in a double-blind trial in viral hepatitis.
3. Key Constituents and Active Compounds
Iridoid Glycosides (The Primary Actives)
The evidence of its hepatoprotective activity, in experimental and clinical studies, accelerated the correlation of the specific phytochemical constituents of P. kurroa with precise pharmacological activities. Iridoid glycosides, particularly picrosides, emerged as the active molecules.
The rhizomes and roots produce a crystalline substance called "Picroliv" or "Kutkin," a combination of two C9-iridoid glycosides (IGs) known as kutkoside. Picroside II and picroside I are found in a ratio of approximately 2:1. Picroliv is an iridoid glycoside mixture containing 60% picroside I and kutkoside in the ratio of 1:1.5. Among the isolated phytochemicals, picroside I and picroside II are regarded as the marker compounds of this plant.
Picrosides I, II, and III, cucurbitacins, and kutkoside are iridoid glycosides identified in the rhizomes of P. kurroa. Bioactive leads, primarily two major principles — picroside I and picroside II — besides many others, are derived from metabolic pathways especially in the underground roots and rhizomes after 3–4 years of plant growth.
Other Phytochemical Classes
Other isolated compounds include apocynin, vanillic acid, picroside III and V, and kutkoside. Similarly, catalpol, picrorhizosides (A–C), 6-feruloyl-catalpol, cucurbitacin, picrorhiza acid, luteolin-5-O-glucoside, picein, and ellagic acid have been isolated. This plant has yielded more than 65 secondary metabolites. Phytoconstituents such as glycosides, alkaloids, cucurbitacins, iridoids, phenolics, and terpenes in P. kurroa have shown promising pharmacological potential.
The major constituents in picrorhiza are the glycosides picroside I, kutkoside, androsin, and apocynin. Androsin is a phenylpropanoid glycoside considered responsible for some of the plant's anti-asthmatic activity in preclinical models.
Key Compound: Apocynin
Apocynin, a key constituent of P. kurroa roots, has been found to exhibit anti-inflammatory properties by inhibiting thromboxane A2 formation, stimulating prostaglandin release, and ultimately preventing bovine platelet aggregation in arachidonic acid-induced inflammation. Pre-clinical evaluation of immunomodulatory activity and activity-guided isolation of active constituents suggest that the inhibitory activity of the diethyl-ether extract can be attributed to apocynin.
4. Established Mechanisms of Action
Antioxidant and Free Radical Scavenging
The hepatoprotective activity of Picrorhiza kurroa is believed to be attributed to the herb's ability to inhibit the generation of oxygen anions and to scavenge free radicals. Research published in Biochemical Pharmacology confirmed that picroliv, picroside I, and kutkoside from P. kurroa are scavengers of superoxide anions.
NF-κB Inhibition and Anti-Inflammatory Signaling
Studies have revealed that picroliv mediates its effects by changing the antioxidant status of cells, downregulating the expressions of c-Jun and c-fos, and inhibiting hypoxia-induced downregulation of insulin-like growth factor-1 and -2. Because prooxidant, proinflammatory, immunomodulatory, and carcinogenic effects have been linked with activation of NF-κB, picroliv can inhibit NF-κB activation.
Picroside II inhibited the increase of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and intercellular adhesion molecule (ICAM)-1 expression. Expression levels of TLR4 and NF-κB were significantly downregulated in the picroside II group, indicating that picroside II treatment suppressed the TLR4/NF-κB signaling pathway, protecting renal tissue against oxidative stress and inflammatory response.
Immunomodulation
Diethyl ether extracts showed potent inhibitory activity towards the classical pathway of the complement system, the respiratory burst of activated polymorphonuclear leukocytes, and mitogen-induced proliferation of T-lymphocytes, as well as anti-inflammatory activity towards carrageenan-induced paw edema. The bitter bioactive compound picroside boosts immunity by enhancing phagocytosis and humoral and cell-mediated immune responses.
Choleretic and Anti-Cholestatic Effects
Picroliv has shown a choleretic effect in rats and anti-cholestatic effect in rats, guinea pigs, and cats treated with paracetamol and ethinyl estradiol. This mechanism underpins its use in jaundice and liver congestion in traditional medicine.
Cell Protection and Hepatocyte Repair
Picroliv exhibits hepatoprotective effects against aflatoxin, oxytetracycline, carbon tetrachloride, paracetamol, and alcohol; protects against ischemia-reperfusion injury of the liver and kidneys; and exhibits anti-inflammatory, immunomodulatory, and anticarcinogenic effects.
5. Scientific Evidence by Area of Use
5.1 Hepatoprotection and Liver Disease
This is the most-studied pharmacological area for P. kurroa. The evidence of its hepatoprotective activity in experimental and clinical studies accelerated the correlation of the specific phytochemical constituents of P. kurroa with precise pharmacological activities.
Animal/Preclinical Evidence: Picroliv has shown efficacy comparable to silymarin in rodent models of galactosamine, paracetamol, thioacetamide, and CCl4-induced hepatic damage. The plant has also been shown to be hepatoprotective in various animal models of hepatotoxicity including carbon tetrachloride, D-galactosamine, paracetamol, and thioacetamide. In a rodent NAFLD model, a hydroalcoholic extract was given at doses of 200 mg/kg and 400 mg/kg b.i.d. orally for 4 weeks to rats challenged with a 30% high-fat diet. Histopathology showed that the extract brought about a reversal of fatty infiltration of the liver and a lowering of hepatic lipids compared to the high-fat diet control group. Compared to the standard dose of silymarin, P. kurroa reduced the lipid content of the liver more significantly at the dose of 400 mg/kg.
Human/Clinical Evidence — Viral Hepatitis: In a randomized, double-blind, placebo-controlled trial in patients diagnosed with acute viral hepatitis (HBsAg negative), P. kurroa root powder at 375 mg three times a day was given for 2 weeks (n=15) or a matching placebo (n=18) was given. Bilirubin, serum glutamic-oxaloacetic transaminase (SGOT), and serum glutamic pyruvic transaminase (SGPT) values were significantly lower in the treatment group when compared to the placebo group. The standardized capsule formulation used in that study contained picroside I ranging from 2.72 to 2.88 mg/capsule and picroside II from 5.50 to 6.00 mg/capsule as verified by HPLC. An earlier commonly used Ayurvedic formulation, Arogyavardhini, containing 50% P. kurroa, was also found effective in a double-blind trial in viral hepatitis.
Evidence Strength and Limitations: While some studies suggest that picrorhiza may help reduce inflammation and improve liver function, particularly in cases of acute viral hepatitis, scientific consensus on its effectiveness remains limited, with many studies lacking the rigorous design necessary for reliable conclusions. These studies often suffer from methodological limitations such as small sample sizes, short duration, and lack of rigorous controls. No large, high-quality randomized controlled trials specifically in cirrhosis patients have been published as of 2024.
5.2 Non-Alcoholic Fatty Liver Disease (NAFLD)
In recent years, P. kurroa's use for fatty liver disease (including non-alcoholic fatty liver disease, NAFLD) has gained scientific interest. Several animal studies and a few small human clinical trials suggest that extracts of P. kurroa exert hepatoprotective effects: they reduce liver fat accumulation, improve liver enzyme levels, and demonstrate antioxidant, anti-inflammatory, and antifibrotic properties. The active constituents, such as picroside I and II and kutkoside, are believed to modulate pathways involved in lipid metabolism and oxidative stress, which are central to fatty liver disease pathogenesis. In view of the increasing prevalence of metabolic syndrome and NAFLD, P. kurroa should be investigated by the reverse pharmacology path as a potential drug for the treatment of NAFLD. Evidence remains preliminary, predominantly derived from animal models, and large human RCTs are lacking.
5.3 Respiratory Disease and Asthma
Preclinical Evidence: Animal studies have investigated the anti-asthmatic compound androsin. Research published in International Archives of Allergy and Applied Immunology found that androsin prevents allergen- and platelet-activating factor (PAF)-induced bronchial obstruction in guinea pigs. The major constituents picroside I, kutkoside, androsin, and apocynin have been shown in animal studies to be antiallergic and to inhibit platelet-activating factor (an important pro-inflammatory molecule).
Human Evidence: Two preliminary trials indicated that picrorhiza may improve breathing ability in asthma patients and reduce the severity of the condition. However, a double-blind follow-up study failed to show a benefit in asthmatic sufferers. Taking picrorhiza by mouth for up to 12 weeks does not seem to help asthma symptoms or improve lung function based on available controlled data. The evidence for asthma is therefore mixed and currently insufficient to support a firm clinical recommendation.
5.4 Vitiligo
Picrorhiza extract appears to modulate the immune system in a way that may produce a beneficial effect on vitiligo, which has been shown to result from a hyperactive immune system. The plant has been observed to aid in repigmentation recovery in vitiligo. A study published in the Journal of Ethnopharmacology in 1989 (Bedi et al.) found that picrorhiza may potentiate photochemotherapy in vitiligo. However, there is little meaningful evidence that it is effective for enhancing response to vaccinations, speeding wound healing, and enhancing the effectiveness of conventional treatment for vitiligo. The vitiligo evidence is thus limited to a small number of early-phase clinical and pharmacological studies.
5.5 Immunomodulation
Picroliv has demonstrated antiviral and immune-stimulant activities. Numerous studies have shown that picrorhiza has tremendous anti-inflammatory, antimicrobial, immunomodulatory, and antimalarial activity, which are attributed to the presence of kutkin, a principal active constituent of this plant. These findings derive largely from in vitro and animal model studies. No rigorous human RCTs specifically evaluating immunomodulatory endpoints have been published as of available literature.
5.6 Antimicrobial Activity
Picrorhiza kurroa inhibits the growth of several pathogenic microorganisms, including Escherichia coli, Staphylococcus aureus, Streptococcus pyogenes, Salmonella typhi, and Klebsiella pneumoniae, whereas the methanolic extract shows activity against Pseudomonas aeruginosa. Picroside I was isolated and showed higher antimicrobial potential in comparison to a standard antibiotic. Picroside I lysed Yersinia enterocolitica cells as observed under scanning electron microscopy, and molecular docking revealed interactions with the dihydrofolate reductase (DHFR) protein of Y. enterocolitica, identifying DHFR as a possible drug target. All antimicrobial data reported to date are from laboratory (in vitro) and preclinical contexts; no human clinical trials in infectious disease have been published.
5.7 Anti-Inflammatory and Arthritis
In preclinical investigation, P. kurroa rhizome extract was tested against carrageenan-induced paw edema and cotton pellet implantation-induced granuloma formation in rats, as well as in lipopolysaccharide-stimulated RAW 264.7 murine macrophages. Pretreatment with P. kurroa rhizome extract inhibited carrageenan-induced paw edema and cotton pellet-induced granuloma formation in a dose-dependent manner. Animal studies also indicate that picrorhiza extract can decrease joint inflammation, and a single open trial suggested that picrorhiza extract may reduce symptoms of rheumatoid arthritis to a limited degree. This evidence is preliminary; no adequately powered, blinded human RCTs for arthritis are available.
5.8 Anti-Diabetic Activity
Rats with artificially induced diabetes were treated with an aqueous extract of P. kurroa at doses ranging from 100 to 200 mg/kg orally for fourteen days; after treatment, measurement of blood glucose level and lipid profile showed that the plant extract greatly reduced the blood glucose level and increased glucose tolerance. This area of investigation remains at the preclinical stage, with no published human clinical trials available.
5.9 Antioxidant and Potential Anti-Neoplastic Activity
The antioxidant and anti-neoplastic activities of methanolic and aqueous extracts of P. kurroa rhizome were investigated. The cytotoxicity of the extracts was tested by XTT assay in MDA-MB-435S (human breast carcinoma), Hep3B (human hepatocellular carcinoma), and PC-3 (human prostate cancer) cell lines. The ability of the extracts to induce apoptosis was also investigated. Both extracts exhibited promising antioxidant potentials. The extracts were also observed to be cytotoxic at the tested dosage and were able to target cells towards apoptosis. These findings are in vitro only; no human oncology trials have been conducted.
6. Dosage Forms and Reported Dosages
Traditional Crude Drug Forms
The traditional Ayurvedic form is the dried, powdered rhizome, used as a decoction, churna (powder), or compound formulation. The part of P. kurroa concerned with medication is 1–3 g of the powdered crude drug.
Dosages Used in Clinical and Preclinical Studies
- Viral hepatitis (human RCT): P. kurroa root powder at 375 mg three times a day was given for 2 weeks (n=15) in a randomized, double-blind, placebo-controlled trial in patients with acute viral hepatitis (HBsAg negative).
- Standardized extract capsules (hepatic disorders): Each capsule containing 100 mg of concentrated extract, used two times per day, reduced the number of hepatic disorders in one reported study.
- NAFLD animal model: A hydroalcoholic extract of P. kurroa was administered at doses of 200 mg/kg and 400 mg/kg b.i.d. orally for a period of 4 weeks in a rat NAFLD model.
- Preclinical hepatotoxicity (rodent): P. kurroa at a dose of 200 mg/kg orally showed a significant reduction in liver lipid content, GOT, and GPT in galactosamine-induced liver injury in rats.
General Reference Ranges Cited in Literature
A typical recommended dose of powdered picrorhiza ranges from 400 to 1,500 milligrams (mg) daily, or an equivalent amount in extract form. These figures are general reference ranges found in the literature rather than clinically validated dose recommendations based on large-scale trials.
7. Body Systems and Health Areas
P. kurroa is known to possess hepatoprotective, neuroprotective, anti-purgative, anti-diabetic, cardioprotective, anti-cancer, anti-oxidant, anti-microbial, immunomodulatory, and anti-spasmodic activities. The primary body systems implicated in both traditional use and available research are:
- Hepatobiliary system: The most extensively investigated area, covering liver protection, jaundice, viral hepatitis, cholestasis, and NAFLD.
- Immune system: Immunomodulation, anti-allergic, and anti-anaphylactic activity have been demonstrated preclinically.
- Respiratory system: Used traditionally for cough, asthma, and febrile respiratory conditions; limited clinical evidence.
- Gastrointestinal system: Bitter tonic, digestive stimulant, laxative, and anti-ulcerogenic activity in animal models.
- Integumentary system (skin): Traditional use and preliminary clinical data in vitiligo and skin disorders.
- Endocrine/metabolic: Preclinical evidence for anti-diabetic and hypolipidemic activity.
- Musculoskeletal: Preclinical anti-inflammatory data with one open-label human observation in rheumatoid arthritis.
8. Safety Considerations and Notable Interactions
General Tolerability
Loose stools and colic have been reported when unprepared picrorhiza rhizomes are used as medicine; however, extracts in alcohol have shown much less tendency to cause such effects. No other adverse effects have been reported with picrorhiza in the available published literature. Preclinical studies confirmed that P. kurroa extract at a dose of 2,000 mg/kg body weight was safe in Wistar rats and might be used in standardized formulations.
Cytochrome P450 Interactions
In vitro studies established the safety profile of P. kurroa rhizome extract with respect to cytochrome P450. It can be concluded that there is very little possibility of herb-drug interaction if it is administered along with other products metabolized by cytochrome P450, and the results confirmed that P. kurroa can be used safely in Ayurvedic formulations. However, advanced study is required to find out whether these inhibitory effects are clinically significant or not. In vivo interaction data in humans are not yet available.
Immunostimulant Caution
Because of documented immunomodulatory activity, autoimmune diseases may be exacerbated by use, as the herb may stimulate the immune system and worsen conditions such as multiple sclerosis (MS), lupus (SLE), or rheumatoid arthritis (RA). This caution is theoretical and based on the known pharmacological profile of the plant's constituents rather than documented clinical adverse events.
Pregnancy and Lactation
Safety during pregnancy and breastfeeding has not been established. Traditional Ayurvedic texts note certain cautions associated with its use, consistent with this gap in formal safety data.
Adulteration Concern
In order to meet market demands, P. kurroa is often adulterated with other species of Picrorhiza and Lagotis cashmeriana Rupr. (Plantaginaceae). This has implications for quality, standardization, and reproducibility of both research findings and commercial preparations.
Overall Evidence Assessment
Other uses have been proposed (e.g., for asthma, liver damage, wound healing, vitiligo), but the medical evidence is not yet conclusive. While some studies suggest that picrorhiza may help reduce inflammation and improve liver function, scientific consensus on its effectiveness remains limited. Despite promising findings regarding its antioxidant properties and potential uses for autoimmune disorders and digestive health, current research has not established definitive medicinal benefits. The overall body of human clinical evidence is small in scale, often methodologically limited, and not yet sufficient to support firm therapeutic recommendations for any indication. The hepatoprotective application has the largest volume of supportive data, including at least one small double-blind human RCT, but replication in larger, more rigorous trials remains necessary.
References
Go back